Suzanne Vento
Northwell Health · 54 works · 2,338 citations · h-index 23
Top works
- Urolithiasis in Pediatric Patients: A Single Center Study of Incidence, Clinical Presentation and Outcome
- Clinical trial of focal segmental glomerulosclerosis in children and young adults
- An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome
- CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease
- Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome
- Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group
- Exposure to bisphenols and phthalates and association with oxidant stress, insulin resistance, and endothelial dysfunction in children
- Health-related quality of life in glomerular disease
- Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome
- Urinary exosomal Wilms' tumor-1 as a potential biomarker for podocyte injury
- Evaluation of Pediatric Patients With Mild-to-Moderate Hypertension: Yield of Diagnostic Testing
- Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis
- Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group
- Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
- Renal Function and exposure to Bisphenol A and phthalates in children with Chronic Kidney Disease
- Phase I Trial of Rosiglitazone in FSGS
- Serially assessed bisphenol A and phthalate exposure and association with kidney function in children with chronic kidney disease in the US and Canada: A longitudinal cohort study
- Treatment of Recurrent Focal Segmental Glomerulosclerosis in Pediatric Kidney Transplant Recipients: Effect of Rituximab
- Evaluation of Failure to Thrive: Diagnostic Yield of Testing for Renal Tubular Acidosis
- Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group